# Levofloxacin

## Cravit IV solution 250mg/50mL

##### 

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | ICRA2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Indications        | Respiratory tract， ENT， GUT infection. Intrauterine infections， cervicitis， uterine adnesxitis， folliculitis. GIT infections， lymphangitis， mild to moderate skin & skin tissue infections.                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | (仿單) Adult: 250-500 mg po/IV 1-2 times daily. Administer 250 mg injection over 30 minutes， 500 mg injection over 60 minutes. (熱病) Adult: 250-750 mg po/IV q24h (depends on indication). For most indications， in patients with normal renal function， the 750 mg dose is preferred. Pediatric (age > 28 days): 16-20 mg/kg/day (divided q12h) (max. 750 mg/day) For oral therapy， avoid concomitant exposure to multivalent cations (Ca， Fe， Al， Mg， Zn) in dairy products， multivitamins and antacids. Cations chelate the drug and prevent absorption. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to quinolones. Pregnancy & lactation. Children & growing adolescents < 18 years. Tendinitis or tendon rupture.                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | Dizziness， GI disturbances， rash， pruritus， vaginitis， genital moniliasis， taste perversion， insomnia， tendinitis. Rarely， anaphylactic reactions， Lyell's syndrome， Stevens-Johnson's syndrome. Gastrointestinal: Diarrhea (ophthalmic， 1% to 2%; oral or intravenous， 5% )， Nausea (ophthalmic， 1% to 2%; oral or intravenous， 7% ) Neurologic: Headache (ophthalmic， 8% to 10% ; oral and intravenous， 6% )                                                                                                                                      |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## Cravit F.C. 500mg

##### 

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | OCRA5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Indications        | Respiratory tract， ENT， GUT infection. Intrauterine infections， cervicitis， uterine adnesxitis， folliculitis. GIT infections， lymphangitis， mild to moderate skin & skin tissue infections.                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | (仿單) Adult: 250-500 mg po/IV 1-2 times daily. Administer 250 mg injection over 30 minutes， 500 mg injection over 60 minutes. (熱病) Adult: 250-750 mg po/IV q24h (depends on indication). For most indications， in patients with normal renal function， the 750 mg dose is preferred. Pediatric (age > 28 days): 16-20 mg/kg/day (divided q12h) (max. 750 mg/day) For oral therapy， avoid concomitant exposure to multivalent cations (Ca， Fe， Al， Mg， Zn) in dairy products， multivitamins and antacids. Cations chelate the drug and prevent absorption. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to quinolones. Epilepsy. History of tendon disorders related to fluoroquinolone administration. Children or growing adolescents. Pregnancy & lactation.                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Nausea & diarrhea， elevated liver transaminases， inj site reactions. Gastrointestinal: Diarrhea (ophthalmic， 1% to 2%; oral or intravenous， 5% )， Nausea (ophthalmic， 1% to 2%; oral or intravenous， 7% ) Neurologic: Headache (ophthalmic， 8% to 10% ; oral and intravenous， 6% )                                                                                                                                                                                                                                                                           |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

